Edding Genor Gets China Approval for Phase 2 GB268 Trial in Colorectal Cancer
MT Newswires Live
3 hours ago
Edding Genor Group Holdings (HKG:6998) received approval from China's National Medical Products Administration for a Phase 2 clinical trial of its investigational drug GB268 in advanced colorectal cancer, according to a Sunday Hong Kong bourse filing.
The trial will evaluate GB268, a PD-1/CTLA-4/VEGF trispecific antibody, in combination with chemotherapy as a first-line treatment for patients with locally advanced or metastatic colorectal cancer that cannot be treated through curative surgery or local therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.